The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study.
 
Takahiro Kogawa
Speakers' Bureau - Daiichi Sankyo
Research Funding - Daiichi Sankyo
 
Kan Yonemori
No Relationships to Disclose
 
Norikazu Masuda
Honoraria - AstraZeneca; Chugai Pharma; Pfizer; Takeda
Research Funding - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Pfizer
 
Shunji Takahashi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; MSD; Novartis; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis
 
Masato Takahashi
Speakers' Bureau - Daiichi Sankyo
 
Hirotaka Iwase
Speakers' Bureau - Daiichi Sankyo
 
Takahiro Nakayama
No Relationships to Disclose
 
Toshiaki Saeki
No Relationships to Disclose
 
Tatsuya Toyama
Speakers' Bureau - Daiichi Sankyo
 
Toshimi Takano
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Novartis; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Puma Biotechnology (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroshi Onuma
Employment - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Hayao Ogawa
Employment - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Yoshimi Tanaka
Employment - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Yoshiko Igari
Employment - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Masahiro Sugihara
Employment - Daiichi Sankyo
 
Michele Vigliotti
Employment - Daiichi Sankyo
Research Funding - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Daiichi Sankyo
 
Channing Yu
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Patents, Royalties, Other Intellectual Property - Co-inventor on patent WO2013138585 A1 / US20150044676
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Martin Sebastian Olivo
Employment - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Suguru Ueno
Employment - Daiichi Sankyo
Patents, Royalties, Other Intellectual Property - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Pfizer
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst)